APR Pharma: what changed
Two fiscal years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
APR Pharma
Largest movements
- Cash -€18,572
down €18,572 (-28.6%), from €65,020 to €46,448
mainly Trade debts (-€101,715) and Investment in fixed assets (net) (-€12,579)
- Intangible fixed assets -€18,115
down €18,115 (-9.2%), from €196,883 to €178,768
- Stocks and contracts +€10,900
new in 2025: €10,900
- Receivables within one year +€7,679
up €7,679 (+662.0%), from €1,160 to €8,839
of which Trade receivables: +€4,570
- Profit (loss) carried forward +€534,279
up €534,279, from -€495,773 to €38,506
- Contributions -€445,000
down €445,000 (-89.0%), from €500,000 to €55,000
- Trade debts -€101,715
down €101,715 (-86.1%), from €118,147 to €16,432
- Other debts -€5,671
down €5,671 (-4.0%), from €140,688 to €135,017
- Gross operating margin +€71,325
up €71,325, from -€667 to €70,657
- Depreciation +€3,559
up €3,559 (+13.1%), from €27,135 to €30,694
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €263,063 | €244,955 | -€18,108 | -6.9% |
| Fixed assets | 21/28 | €196,883 | €178,768 | -€18,115 | -9.2% |
| Intangible fixed assets | 21 | €196,883 | €178,768 | -€18,115 | -9.2% |
| Current assets | 29/58 | €66,180 | €66,187 | +€7 | 0.0% |
| Stocks and contracts in progress | 3 | - | €10,900 | +€10,900 | |
| Stocks | 30/36 | - | €10,900 | +€10,900 | |
| Amounts receivable within one year | 40/41 | €1,160 | €8,839 | +€7,679 | +662.0% |
| Trade receivables | 40 | €647 | €5,217 | +€4,570 | +706.5% |
| Other amounts receivable | 41 | €513 | €3,621 | +€3,108 | +605.8% |
| Cash at bank and in hand | 54/58 | €65,020 | €46,448 | -€18,572 | -28.6% |
| Total equity and liabilities | 10/49 | €263,063 | €244,955 | -€18,108 | -6.9% |
| Equity | 10/15 | €4,227 | €93,506 | +€89,279 | +2111.9% |
| Contributions | 10/11 | €500,000 | €55,000 | -€445,000 | -89.0% |
| Profit (loss) carried forward | 14 | -€495,773 | €38,506 | +€534,279 | |
| Amounts payable | 17/49 | €258,836 | €151,449 | -€107,386 | -41.5% |
| Amounts payable within one year | 42/48 | €258,836 | €151,449 | -€107,386 | -41.5% |
| Trade debts | 44 | €118,147 | €16,432 | -€101,715 | -86.1% |
| Suppliers | 440/4 | €118,147 | €16,432 | -€101,715 | -86.1% |
| Other amounts payable | 47/48 | €140,688 | €135,017 | -€5,671 | -4.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €27,135 | €30,694 | +€3,559 | +13.1% |
| Other operating charges | 640/8 | €387 | €661 | +€274 | +70.6% |
| Gross operating margin | 9900 | -€667 | €70,657 | +€71,325 | |
| Operating profit (loss) | 9901 | -€28,190 | €39,303 | +€67,493 | |
| Financial income | 75/76B | - | €6 | +€6 | |
| Recurring financial income | 75 | - | €6 | +€6 | |
| Financial charges | 65/66B | €30 | €30 | = | 0.0% |
| Recurring financial charges | 65 | €30 | €30 | = | 0.0% |
| Profit (loss) for the period before taxes | 9903 | -€28,220 | €39,279 | +€67,499 | |
| Profit (loss) for the period | 9904 | -€28,220 | €39,279 | +€67,499 | |
| Profit (loss) for the period to be appropriated | 9905 | -€28,220 | €39,279 | +€67,499 |
Source: filed annual accounts (NBB), fiscal years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 5 October 2026 via checked.be.